PHAXIAM Therapeutics SA (DELISTED) (PHXM:DL)
3.10
0.00 (0.00%)
USD |
NASDAQ |
Mar 11, 16:00
PHAXIAM Therapeutics EPS Diluted (Quarterly): -1.020 for Sept. 30, 2023
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | -1.020 |
| December 31, 2022 | 1.957 |
| September 30, 2022 | -1.669 |
| June 30, 2022 | 3.739 |
| March 31, 2022 | -4.309 |
| December 31, 2021 | -4.504 |
| September 30, 2021 | -5.757 |
| June 30, 2021 | -7.297 |
| March 31, 2021 | -6.658 |
| December 31, 2020 | -11.74 |
| Date | Value |
|---|---|
| September 30, 2020 | -11.45 |
| June 30, 2020 | -10.66 |
| March 31, 2020 | -10.82 |
| December 31, 2019 | -11.98 |
| September 30, 2019 | -8.673 |
| June 30, 2019 | -11.04 |
| March 31, 2019 | -7.386 |
| December 31, 2018 | -5.488 |
| September 30, 2018 | -6.977 |
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Quarterly) Range, Past 5 Years
-11.98
Minimum
Dec 2019
3.739
Maximum
Jun 2022
-6.367
Average
-6.978
Median
EPS Diluted (Quarterly) Benchmarks
| DBV Technologies SA | -0.14 |
| Cellectis SA | -0.15 |
| Genfit SA | -- |
| Innate Pharma SA | -- |
| Inventiva SA | -- |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -6.195M |
| Total Expenses (Quarterly) | 6.268M |
| Enterprise Value | -8.542M |
| Earnings Yield | 96.99% |